To The Moon

$Dow Chemical(DOW)$ $DuPont de Nemours Inc(DD)$

Dow Inc. (DOW) and DuPont de Nemours, Inc. (DD) are two of America’s most prominent chemical manufacturers, each producing a diverse range of chemicals and materials for a wide spectrum of industries. Both companies share a rich, intertwined history, most notably their high-profile merger in 2017 and subsequent separation into independent publicly traded entities in 2019.

Today, Dow and DuPont operate as restructured, standalone firms with diversified portfolios serving key end markets like packaging, electronics, construction, automotive, and agriculture. Against a backdrop of demand softness in several segments and the added challenge of trade tariffs, investors are keen to understand which company presents a more compelling investment case in the current environment.

Why Compare Dow and DuPont Now?

With the chemical industry facing cyclical and geopolitical headwinds, it is critical to assess which of these two leaders is better positioned to navigate near-term challenges and deliver long-term shareholder value. Both are executing strategic initiatives, but their approaches and risk profiles differ.

Let’s dive deeper into each company’s fundamentals to see which one might suit investors’ portfolios better at this juncture.

Dow: Focus on Cost Advantage and Cash Discipline

Dow benefits from a differentiated portfolio and low-cost feedstock positions, enabling it to compete effectively even in difficult markets. The company continues to invest in high-return, accretive projects, although it recently paused construction of its Fort Saskatchewan Path2Zero project due to macroeconomic and geopolitical uncertainties.

Still, Dow remains committed to growth opportunities in resilient end markets, such as pharmaceuticals and personal care. Its alkoxylation expansion in Seadrift, Texas, is expected to come online by mid-2025, adding to earnings in the second half of next year.

Aggressive Cost-Cutting to Preserve Margins

To mitigate current market pressures, Dow is implementing a comprehensive plan expected to deliver about $6 billion in cash support. This includes selling infrastructure assets, cutting operating costs, and reducing capital expenditures.

Dow is targeting $1 billion in annual cost savings, primarily through labor and direct expense reductions, including a global workforce cut of roughly 1,500 positions. These efforts are projected to deliver about $300 million in benefits by 2025 and fully materialize by 2026. Additionally, management anticipates trimming $1 billion from capex next year, largely from deferring Path2Zero investments.

A Strong Balance Sheet and Attractive Dividend

Dow’s robust financial position underpins its strategic flexibility and shareholder returns. At the end of Q1, Dow had over $11 billion in liquidity, including $1.5 billion in cash. In 2024, the company returned $2.5 billion to shareholders, split between $2 billion in dividends and $500 million in buybacks. Another $494 million in dividends was paid in Q1 2025.

Currently, Dow offers a very attractive dividend yield of 9.7%. Although the payout ratio is high at 239%, management’s strong cash discipline suggests the dividend remains sustainable in the near term.

Headwinds Cloud Near-Term Outlook

Despite its strengths, Dow faces ongoing challenges. European markets remain weak, especially in construction and consumer durables, with inflation and low confidence weighing on demand. Automotive demand in Europe is also soft, and trade tensions continue to dampen sentiment in building materials and durable goods.

Dow’s Performance Materials & Coatings segment has been particularly impacted by weak siloxane prices, a result of oversupply and competitive pricing pressure from increased capacity in China. While new capacity additions are slowing, oversupply is likely to keep siloxane prices under pressure in the near term.

DuPont: Innovation-Led Growth in Resilient Markets

DuPont, meanwhile, is leveraging its innovation and R&D capabilities to drive growth in high-value markets. The company remains focused on customer-driven product development across several fast-growing segments.

Notably, DuPont has expanded its healthcare portfolio through strategic acquisitions. The purchase of Spectrum Plastics Group strengthened its position in medical devices and components, while the acquisition of Donatelle Plastics brought advanced capabilities like precision machining, injection molding, and device assembly. These moves align with DuPont’s strategy of building scale in resilient healthcare markets.

Cost Savings and Strong Cash Flow

DuPont is also realizing benefits from cost synergies and productivity initiatives. Structural cost actions are expected to deliver additional savings in 2025, and the company has been able to implement price increases to offset inflationary pressures. Recent restructuring actions are projected to save $150 million annually.

Cash generation and capital discipline remain central to DuPont’s strategy. Thanks to strong working capital management, it achieved adjusted free cash flow conversion of 105% in 2024, and it expects to maintain conversion above 90% in 2025 despite separation-related costs.

Steady Dividend Growth and Capital Allocation

DuPont continues to reward shareholders with steady dividend growth. In February 2025, it raised its quarterly dividend by 8% to $0.41 per share. The company paid $635 million in dividends in 2024 and expects to distribute around $690 million this year. At current levels, DD offers a 2.4% dividend yield with a conservative payout ratio of 38%, supported by a five-year annualized dividend growth rate of approximately 7.1%.

Short-Term Challenges

However, DuPont also faces its own set of headwinds. Weakness in construction and automotive markets — due to high interest rates, inflation, and sluggish build rates in the U.S. and Europe — has pressured its diversified industrials segment.

In addition, the upcoming separation of DuPont’s electronics business, set for November 1, 2025, is expected to cost just under $700 million, most of which will hit this year. These costs will likely weigh on margins and cash conversion in 2025. In Q1 alone, DuPont recorded $79 million in separation-related expenses.

Price Performance and Valuation of DOW & DD

The DOW stock is down 29.4% year to date, while DD has lost 10.7% compared with the Zacks Chemicals Diversified industry’s decline of 15.6%.

DOW is currently trading at a forward 12-month earnings multiple of 45.80. This represents a roughly 158% premium when stacked up with the industry average of 17.73X.

DD is currently trading at a forward 12-month earnings multiple of 15.45, below DOW and the industry.

Key Insights at a Glance

1. Dow’s differentiated, low-cost portfolio and disciplined cash actions help it weather tough markets, but cyclical demand weakness remains a drag.

2. Dow offers a sky-high 9.7% dividend yield, though its high payout ratio and earnings pressure make it riskier.

3. Dow is executing a $6 billion cash-support plan, including cost cuts, capex reductions, and asset sales.

4. Dow faces siloxane oversupply, weak European construction, and inflation-related demand headwinds.

5. DuPont is leveraging innovation and acquisitions to grow in healthcare, expanding its advanced materials expertise.

6. DuPont delivers strong free cash flow and steady dividend growth, with a modest 2.4% yield backed by a low payout ratio.

7. DuPont faces challenges from housing and automotive market softness, as well as significant costs tied to its electronics spin-off.

8. Both companies are restructuring and repositioning for long-term competitiveness, but with differing risk-return profiles.

Final Takeaways: Which Is the Better Buy?

Dow and DuPont each offer compelling — yet distinct — investment propositions. Dow is more suited for investors seeking maximum current income and willing to accept elevated risk tied to cyclical markets and high payout ratios. Its cost discipline and cash support plan help underpin its generous dividend and long-term prospects.

DuPont, on the other hand, provides a steadier, more sustainable growth trajectory, fueled by innovation and disciplined capital allocation. Its lower payout ratio, consistent dividend growth, and exposure to resilient healthcare markets make it a more conservative choice for risk-averse investors.

Ultimately, the better buy depends on your investment priorities. If income and yield are paramount and you can tolerate volatility, Dow may be more attractive. If you prefer stability, lower payout risk, and a focus on long-term growth, DuPont could be the better option.

Both companies are navigating a challenging market landscape while laying the foundation for future growth — and both merit a place on investors’ watchlists.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub